Cardiff Oncology (CRDF)
(Delayed Data from NSDQ)
$2.35 USD
+0.10 (4.44%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $2.36 +0.01 (0.43%) 6:48 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
CRDF 2.35 +0.10(4.44%)
Will CRDF be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CRDF based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRDF
Take the Zacks Approach to Beat the Markets: Navios Maritime, Coinbase Global, Virtu Financial in Focus
Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates
CRDF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cardiff Oncology (CRDF) Is a Great Choice for 'Trend' Investors, Here's Why
Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why
Here's Why Momentum in Cardiff Oncology (CRDF) Should Keep going
Other News for CRDF
Cardiff Oncology to Present at the Jefferies Healthcare Conference
Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data
Cardiff Oncology to Present at Upcoming Investor Conferences in May
The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028
Buy Rating Affirmed on Cardiff Oncology as Phase 2 Trial Shows Promise for Accelerated Approval